Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin

  • Authors:
    • Zhenni Sun
    • Lu Yue
    • Zan Shen
    • Yong Li
    • Aihua Sui
    • Tianjun Li
    • Qian Tang
    • Ruyong Yao
    • Yongning Sun
  • View Affiliations

  • Published online on: February 13, 2017     https://doi.org/10.3892/ol.2017.5722
  • Pages: 2377-2384
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nucleophosmin (NPM) and human epidermal growth factor receptor‑2 (Her‑2) are abnormally expressed in various types of human malignant tumors, including gastric cancer, and have been closely associated with cancer chemoresistance. However, their interaction and roles in oxaliplatin resistance are not fully understood. Therefore, the present study aimed to elucidate the relationship between NPM and Her‑2 in gastric cancer cell lines and clinical samples, and further investigated their role in the resistance of gastric cancer to oxaliplatin. Western blotting and reverse transcription‑quantitative polymerase chain reaction confirmed that NPM and Her‑2 expression were significantly upregulated in gastric cancer cells and clinical samples, and that their expression levels were strongly correlated. However, Her‑2 expression was not affected by upregulation or downregulation of NPM expression in gastric cancer cells. Cell counting kit‑8 assays demonstrated that the cell sensitivity to oxaliplatin decreased simultaneously with an increase in NPM expression. Furthermore, inhibition of Her‑2 expression using trastuzumab significantly increased the sensitivity of the cells to oxaliplatin, which occurred simultaneously with the downregulation of NPM. These results indicated that inhibition of NPM, as a Her‑2 downstream signal, may be a novel strategy to overcome oxaliplatin‑resistant gastric cancer, and that trastuzumab and oxaliplatin may exhibit a synergistic antitumor effect in Her‑2‑positive gastric cancer cells.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun Z, Yue L, Shen Z, Li Y, Sui A, Li T, Tang Q, Yao R and Sun Y: Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin. Oncol Lett 13: 2377-2384, 2017
APA
Sun, Z., Yue, L., Shen, Z., Li, Y., Sui, A., Li, T. ... Sun, Y. (2017). Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin. Oncology Letters, 13, 2377-2384. https://doi.org/10.3892/ol.2017.5722
MLA
Sun, Z., Yue, L., Shen, Z., Li, Y., Sui, A., Li, T., Tang, Q., Yao, R., Sun, Y."Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin". Oncology Letters 13.4 (2017): 2377-2384.
Chicago
Sun, Z., Yue, L., Shen, Z., Li, Y., Sui, A., Li, T., Tang, Q., Yao, R., Sun, Y."Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin". Oncology Letters 13, no. 4 (2017): 2377-2384. https://doi.org/10.3892/ol.2017.5722